Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | KHK | P50053 | 7/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
| ▸ | LCAT | P04180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089740 | 0.80 | CHRM4 (0.48) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL26089090 | 0.80 | CHRM4 (0.48) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL12683424 | 0.79 | OGA (0.42) | SLC6A9CHRNA7PARP1OGALCAT | |
| SCHEMBL25187820 | 0.79 | KMT2A (0.57) | — | |
| SCHEMBL25181015 | 0.79 | HSD11B1 (0.39) | HSD11B1CHRNA7CHRM4 | |
| SCHEMBL23459168 | 0.78 | CHRM2 (0.54) | HSD11B1SLC6A9CHRM2CHRM5CHRM1 | |
| SCHEMBL23459164 | 0.78 | CHRM2 (0.54) | HSD11B1SLC6A9CHRM2CHRM5CHRM1 | |
| SCHEMBL23459171 | 0.78 | CHRM2 (0.54) | HSD11B1SLC6A9CHRM2CHRM5CHRM1 | |
| SCHEMBL26087229 | 0.77 | RBP4 (0.39) | HSD11B1KHKPDE10ACHRM2CHRM5 | |
| Hydrochloric Acid SCHEMBL23459169 | 0.77 | CHRM2 (0.53) | HSD11B1SLC6A9CHRM2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | HSD11B1 2289/4885SLC6A9 2858/4885KHK 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.